Welcome to our dedicated page for Intellia Therape SEC filings (Ticker: NTLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Intellia Therapeutics, Inc. filings document the business, governance and capital structure of a Nasdaq-listed clinical-stage biopharmaceutical company developing CRISPR-based therapies. Its Form 8-K reports record quarterly financial results and business updates, clinical and regulatory disclosures for lonvo-z in hereditary angioedema, nex-z in ATTR amyloidosis, and related FDA communications.
The filing record also includes common stock financing disclosures, including an underwritten public offering and amendments to an at-the-market sales program. Proxy materials describe annual meeting matters, executive compensation, equity awards and board governance, while bylaw amendments and other corporate filings address shareholder proposal procedures, forum provisions and registered common stock listed on The Nasdaq Global Market.
Intellia Therapeutics reported first quarter 2026 results alongside major clinical milestones. In the Phase 3 HAELO trial, a one-time infusion of lonvo-z reduced hereditary angioedema attacks by 87% versus placebo over six months, with 62% of treated patients attack free and therapy free.
Intellia has begun a rolling BLA submission for lonvo-z and is targeting a potential U.S. launch in the first half of 2027. The FDA lifted clinical holds on the MAGNITUDE and MAGNITUDE-2 Phase 3 trials for nex-z in ATTR amyloidosis, and patient screening has resumed.
Financially, Q1 2026 collaboration revenue was $15.0 million and net loss was $96.2 million, or $0.81 per share. Cash, cash equivalents and marketable securities were $517.2 million as of March 31, 2026, and an April underwritten equity offering added approximately $207 million in gross proceeds, supporting operations at least into 2028.
Intellia Therapeutics entered an underwriting agreement for a public offering of 16,744,187 shares of common stock at $10.75 per share, with underwriters exercising a 30‑day option for an additional 2,511,628 shares. The company estimates net proceeds of about $194.6 million.
Intellia plans to use the funds to advance clinical development and prepare for commercial launch of its lead programs, support other pipeline research, pursue potential acquisitions, and for working capital and general corporate purposes. It expects these proceeds, together with existing cash and collaboration funding, to fund operations at least into 2028.
Intellia also reported preliminary unaudited cash, cash equivalents and marketable securities of about $517.2 million as of March 31, 2026, including roughly $33.6 million in net proceeds from at‑the‑market stock sales during the quarter.
Intellia Therapeutics, Inc. will hold its 2026 Annual Meeting of Stockholders virtually on June 9, 2026 at 9:00 a.m. Eastern Time. Stockholders of record as of April 10, 2026 may vote on three main items: electing three class I directors, ratifying Deloitte & Touche LLP as independent auditor for 2026, and approving on a non-binding advisory basis the compensation of named executive officers. The board unanimously recommends voting in favor of all three proposals. The proxy statement also explains virtual attendance and voting procedures, quorum and vote standards, board composition, governance practices, and committee structures, including audit, compensation, nominating and science and technology committees.
Intellia Therapeutics Inc Schedule 13G filed by Vanguard Capital Management reports beneficial ownership of 5,945,571 shares of common stock, representing 5.03% of the class. The filing shows sole voting power for 861,466 shares and sole dispositive power for 5,945,571 shares. The filing lists CUSIP 45826J105 and is signed April 30, 2026.
Intellia Therapeutics is offering 16,744,187 shares of common stock. The prospectus supplement dated April 28, 2026 sets a public offering price of $10.75 per share and shows estimated net proceeds to the company of approximately $169.2 million before expenses.
The underwriters have a 30-day option to purchase up to an additional 2,511,628 shares. The registration assumes 116,317,060 shares outstanding as of December 31, 2025. The offering proceeds are intended to advance clinical development, prepare for commercial launch, fund R&D and general corporate purposes.
Intellia Therapeutics Inc Schedule 13G shows Vanguard Portfolio Management beneficially owned 6,266,007 shares of common stock, representing 5.3% of the class as of 03/31/2026. The filing states Vanguard entities exercise dispositive power over these shares and that the position includes securities held for Vanguard funds and managed accounts. The filing was signed on 04/29/2026.
Intellia Therapeutics is offering $150,000,000 of its common stock under a preliminary prospectus supplement dated April 27, 2026. The prospectus supplement is part of an automatic shelf registration (Form S-3ASR, File No. 333-275740) and states the shares will trade on Nasdaq under the symbol NTLA.
The supplement cites key program updates for lonvo-z (NTLA-2002), including positive Phase 3 topline results and a rolling BLA submission, and provides preliminary cash figures: approximately $517.2 million in cash, cash equivalents and marketable securities as of March 31, 2026. Shares outstanding were 116,317,060 as of December 31, 2025.
Intellia Therapeutics is offering $150,000,000 of its common stock under a preliminary prospectus supplement dated April 27, 2026. The prospectus supplement is part of an automatic shelf registration (Form S-3ASR, File No. 333-275740) and states the shares will trade on Nasdaq under the symbol NTLA.
The supplement cites key program updates for lonvo-z (NTLA-2002), including positive Phase 3 topline results and a rolling BLA submission, and provides preliminary cash figures: approximately $517.2 million in cash, cash equivalents and marketable securities as of March 31, 2026. Shares outstanding were 116,317,060 as of December 31, 2025.
Intellia Therapeutics is offering $150,000,000 of its common stock under a preliminary prospectus supplement dated April 27, 2026. The prospectus supplement is part of an automatic shelf registration (Form S-3ASR, File No. 333-275740) and states the shares will trade on Nasdaq under the symbol NTLA.
The supplement cites key program updates for lonvo-z (NTLA-2002), including positive Phase 3 topline results and a rolling BLA submission, and provides preliminary cash figures: approximately $517.2 million in cash, cash equivalents and marketable securities as of March 31, 2026. Shares outstanding were 116,317,060 as of December 31, 2025.
Intellia Therapeutics reported positive Phase 3 HAELO trial results for its in vivo CRISPR gene-editing candidate lonvoguran ziclumeran (lonvo-z) in hereditary angioedema. In the 80‑patient, placebo‑controlled study, lonvo-z achieved an 87% reduction in HAE attack rate versus placebo between weeks 5 and 28 and 62% of treated patients were completely attack‑free and off prophylactic therapy in that period. All 52 patients in the lonvo-z arm saw attack‑rate reductions, and early crossover data showed attack rates approaching zero in both arms. Safety appeared favorable, with no serious adverse events or grade ≥3 treatment‑emergent events reported in the lonvo-z group and mainly mild or moderate infusion‑related reactions. Intellia has initiated a rolling biologics license application with the FDA and is preparing to complete the submission in the second half of 2026 and for a potential U.S. launch in the first half of 2027, if approved.
Intellia Therapeutics reported positive Phase 3 HAELO trial results for its in vivo CRISPR gene-editing candidate lonvoguran ziclumeran (lonvo-z) in hereditary angioedema. In the 80‑patient, placebo‑controlled study, lonvo-z achieved an 87% reduction in HAE attack rate versus placebo between weeks 5 and 28 and 62% of treated patients were completely attack‑free and off prophylactic therapy in that period. All 52 patients in the lonvo-z arm saw attack‑rate reductions, and early crossover data showed attack rates approaching zero in both arms. Safety appeared favorable, with no serious adverse events or grade ≥3 treatment‑emergent events reported in the lonvo-z group and mainly mild or moderate infusion‑related reactions. Intellia has initiated a rolling biologics license application with the FDA and is preparing to complete the submission in the second half of 2026 and for a potential U.S. launch in the first half of 2027, if approved.
Intellia Therapeutics reported positive Phase 3 HAELO trial results for its in vivo CRISPR gene-editing candidate lonvoguran ziclumeran (lonvo-z) in hereditary angioedema. In the 80‑patient, placebo‑controlled study, lonvo-z achieved an 87% reduction in HAE attack rate versus placebo between weeks 5 and 28 and 62% of treated patients were completely attack‑free and off prophylactic therapy in that period. All 52 patients in the lonvo-z arm saw attack‑rate reductions, and early crossover data showed attack rates approaching zero in both arms. Safety appeared favorable, with no serious adverse events or grade ≥3 treatment‑emergent events reported in the lonvo-z group and mainly mild or moderate infusion‑related reactions. Intellia has initiated a rolling biologics license application with the FDA and is preparing to complete the submission in the second half of 2026 and for a potential U.S. launch in the first half of 2027, if approved.